Awake Extracorporeal Membrane Oxygenation (ECMO) for Acute Respiratory Failure A Non-controlled, Single-center, Investigator-initiated Prove-of-concept Study
ECMO
+ ECMO in non-intubated patients
Treatment Study
Summary
Study start date: August 1, 2012
Actual date on which the first participant was enrolled.Pilot study in 6 patients with ARDS addressing the use of awake veno-venous ECMO to avoid endotracheal intubation and mechanical ventilation
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.6 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Patients aged 18-75 yrs with acute respiratory failure due to ARDS or pneumonia fulfilling standard criteria for endotracheal intubation * Severe and progressive hypoxemia, i.e. PaO2 \< 60 mmHg or SaO2 \< 90% on O2 \> 10 l/min not tolerating noninvasive ventilation, or * PaO2/FiO2 \< 200 not improving or deteriorating on noninvasive ventilation, or * Respiratory distress and hypoxemia not fulfilling the criteria above with clinical impression of the ICU attending that intubation and mechanical ventilation are mandated * Patient considered eligible by at least two investigators of this study Exclusion Criteria: * Patient does not fulfill the inclusion criteria * Uncontrolled malignancy * Severe and untreatable coagulation or bleeding disorders (INR \> 2,0; aPTT \> 60s, Platelet count \< 50.000/µl, all after substitution) * Stroke within the past 3 months * Uncontrolled sepsis or septic shock * Multiorgan failure involving \> 2 organ systems * Norepinephrine dose \> 1 mg/h * Hyperdynamic circulation, indicated by cardiac index \> 4.0 l/min/m2 (measured by PiCCO or Swan-Ganz catheter), or SvO2 \> 80% * Cardiac pump failure, indicated by echocardiography (EF \< 40%), PiCCO or Swan Ganz catheter (CI \< 2,5 l/min/m2 despite adequate volume management), or SvO2 \< 50% (provided Hb \> 9,0 g/dl and SaO2 \> 90%), or the need for inotropes (dobutamine, epinephrine, levosimendan) * Clinical or echocardiographic signs of pulmonary hypertension with right ventricular dysfunction * APACHE-II score15 \< 25 * Other conditions suggesting that the patient would benefit from intubation and mechanical ventilation * Severe neurological disorders * Estimated mortality due to severity of acute and/or underlying illness \> 50%
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location